Spinal cord injury company NervGen raises $10M IPO

NervGen Pharma raised $10 million in an IPO on TSX Ventures on March 13. It plans to submit an IND late this year for lead candidate, NVG-291, to treat spinal cord injury and peripheral nerve injury and begin a Phase I trial in 2020.

NervGen Pharma Corp. (TSX-V:NGEN) was founded in 2017 based on technology from the lab of neuroscientist Jerry Silver at Case Western Reserve University. Silver's team showed that protein tyrosine phosphatase receptor type S (PTPRS) inhibits nerve growth and identified a PTPRS inhibitor that could help promote recovery after SCI...